AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20358390
Drug: Topical SLS
RxNorm normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical SLS 0.25%
Trial: 20358390
Drug: Topical SLS
RxNorm normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical SLS 0.5%
Trial: 20358390
Drug: Topical SLS
RxNorm normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical SLS 1%
Trial: 20358390
Drug: Topical SLS
RxNorm normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical SLS 2%
Trial: 20358390
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin 1%
Trial: 11347858
Drug: lacidipine 4
RxNorm normalized name: lacidipine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lacidipine 4 mg o.d. (increased to 6 mg if needed)
Trial: 11347858
Drug: amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amlodipine 5 mg o.d. (increased to 10 mg if needed)
Trial: 11347858
Drug: lacidipine 6
RxNorm normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lacidipine 6 mg (for patients requiring dose increase)
Trial: 11347858
Drug: amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine 10 mg (for patients requiring dose increase)
Trial: 8973988
Drug: 7-day 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day 17 beta-estradiol transdermal delivery system (TDS) applied to the abdomen
Trial: 8973988
Drug: 7-day 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day 17 beta-estradiol transdermal delivery system (TDS) applied to the buttocks
Trial: 1316059
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg lomefloxacin orally once daily (n = 259)
Trial: 1316059
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg cefaclor every 8 hours (n = 263)
Trial: 1316059
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg cefaclor
Trial: 24912466
Drug: Ratings based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ratings based on entire therapy sessions
Trial: 18246429
Drug: Second-generation antipsychotics
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antipsychotics (SGAs: olanzapine, quetiapine, risperidone, ziprasidone)
Trial: 18246429
Drug: First-generation antipsychotic
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation antipsychotic (FGA: perphenazine)
Trial: 15766337
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose regimen of diamorphine 0.4 mg in hyperbaric bupivacaine 0.5% 2.4 ml
Trial: 15766337
Drug: Adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted dose regimen of diamorphine 0.4 mg in hyperbaric bupivacaine 0.5%
Trial: 12527943
Drug: BB-10010 with
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BB-10010 with dose-intensified BEMOP/CA chemotherapy
Trial: 11029510
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (letrozole, anastrozole, exemestane)
Trial: 9165692
Drug: BY841 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BY841 (50 mg or 100 mg twice daily)
Trial: 9165692
Drug: Omeprazole (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (standard dose)
Trial: 10148879
Drug: Patient-controlled administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled administration of fentanyl (n=37)
Trial: 10148879
Drug: Nurse administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse administration on demand (n=43)
Trial: 22444188
Drug: μ-opioid agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: μ-opioid agonist alfentanil
Trial: 17209211
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation at 4 mg/d for high-risk women and 0.4 mg/d for others
Trial: 12182055
Drug: L-thyroxine suppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-thyroxine suppressive therapy
Trial: 9408856
Drug: Mizolastine (tablet)
RxNorm normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine (tablet)
Trial: 9408856
Drug: Mizolastine (capsule)
RxNorm normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine (capsule)
Trial: 9408856
Drug: Mizolastine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine (intravenous infusion)
Trial: 28081304
Drug: ACpT (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACpT (4 cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 followed by 4 cycles of paclitaxel 175 mg/m2)
Trial: 28081304
Drug: ACdT (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACdT (4 cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 followed by 4 cycles of docetaxel 75 mg/m2)
Trial: 25458980
Drug: Higher-flow nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-flow nasal cannula oxygen at 15 L/minute
Trial: 25458980
Drug: Lower-flow nasal
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-flow nasal cannula oxygen at 6 L/minute
Trial: 9579448
Drug: Oral tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tamoxifen 20 mg/day
Trial: 21899210
Drug: Betamethasone i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone i.m. (BSP 2 mg and BDP 5 mg)
Trial: 29932416
Drug: Bretol® patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bretol® patch (test drug)
Trial: 29932416
Drug: Hokunalin® patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hokunalin® patch (reference drug)
Trial: 9131723
Drug: Clozapine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (up to 450 mg)
Trial: 9131723
Drug: Zotepine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zotepine (up to 450 mg)
Trial: 7703598
Drug: Glucose (1
RxNorm normalized name: Fludeoxyglucose (18F)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose (1 g/kg body wt)
Trial: 7703598
Drug: Fructose (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (1 g/kg body wt)
Trial: 26494450
Drug: Sapropterin (BH4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapropterin (BH4, a nitric oxide synthase cofactor; 10 mg/kg)
Trial: 21302035
Drug: HTUPA 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTUPA 10 mg
Trial: 21302035
Drug: HTUPA 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTUPA 20 mg
Trial: 21302035
Drug: HTUPA 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTUPA 30 mg
Trial: 15335019
Drug: Complex dietary
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex dietary therapy including soy isoflavones and selenium
Trial: 10930895
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin for 5 days, followed by subcutaneous heparin for 5 weeks (n=8)
Trial: 10930895
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous hydrocortisone for 5 days followed by oral prednisolone 40 mg daily, reducing by 5 mg per day each week (n=12)
Trial: 9780100
Drug: Adjunctive daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive daunorubicin perfusion during standardized surgery
Trial: 7530621
Drug: Conventional Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional Insulin Therapy (CIT; n = 12)
Trial: 7530621
Drug: Continuous Subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Subcutaneous Insulin Infusion (CSII; n = 12)
Trial: 7530621
Drug: Intraportal Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraportal Insulin Infusion (IPII; n = 12)
Trial: 7530621
Drug: Intensified insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensified insulin therapy (CSII)
Trial: 7530621
Drug: Intensified insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensified insulin therapy (IPII)
Trial: 29633812
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% at 8 mL/h (Control)
Trial: 29633812
Drug: Ropivacaine 0.4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.4% at 4 mL/h
Trial: 25287553
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (10-14 sessions: 6-10 during pregnancy and 4-8 after delivery)
Trial: 12765983
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (dalteparin) or an invasive strategy
Trial: 14555594
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 500 microg once-daily
Trial: 14555594
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 100 or 200 microg once-daily
Trial: 14555594
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) twice-daily (100, 200, or 500 microg)
Trial: 1352011
Drug: Chlorhexidine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine (60 ml chlorhexidine diacetate 2 g/l)
Trial: 31028503
Drug: Critical group
RxNorm normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Critical group (Routine treatment)
Trial: 26265641
Drug: Three intravitreal
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three intravitreal injections of bevacizumab (IVB) at monthly intervals.
Trial: 22117981
Drug: Prophylactic palonosetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic palonosetron 0.075 mg, intravenously before induction of inhalation anaesthesia
Trial: 22117981
Drug: TIVA using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVA using propofol (target blood concentration 2.5‐6.0 μg/ml) and remifentanil (target blood concentration 2.5‐6.0 ng/ml)
Trial: 19497624
Drug: Oral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estrogen replacement therapy (ERT)
Trial: 11099873
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen replacement therapy (ERT)
Trial: 17279193
Drug: Smaller multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smaller multivitamin tablets
Trial: 17279193
Drug: Multivitamin tablets
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multivitamin tablets with less iron content
Trial: 17279193
Drug: Standard multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard multivitamin tablets (larger size, higher iron content)
Trial: 7969611
Drug: Intensive care
RxNorm normalized name: Rapifen Intensive Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive care treatment for more than 30 days
Trial: 28860166
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg ×3/day)
Trial: 20621454
Drug: Oral olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral olanzapine supplementation
Trial: 20621454
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection (olanzapine-LAI)
Trial: 16774958
Drug: Verteporfin enhanced
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin enhanced feeder vessel therapy with varying light doses (50 J/cm2, 100 J/cm2, 125 J/cm2, 150 J/cm2)
Trial: 10886051
Drug: Fedotozine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fedotozine (30 mg, t.d.s.)
Trial: 30001944
Drug: 900 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 μg of salbutamol
Trial: 28557652
Drug: Clomiphene Citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene Citrate (CC) + Metformin (MET)
Trial: 28557652
Drug: Letrozole (LE)
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole (LE) + Metformin (MET)
Trial: 23893190
Drug: Sublingual specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual specific immunotherapy (SLIT) for three years
Trial: 23893190
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (never treated with specific immunotherapy, only symptomatic drugs)
Trial: 18371963
Drug: Endometrin 100
RxNorm normalized name: Endometrin 100mg Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrin 100 mg twice daily
Trial: 18371963
Drug: Endometrin 100
RxNorm normalized name: Endometrin 100mg Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrin 100 mg three times daily
Trial: 18371963
Drug: P(4) 90
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P(4) 90 mg 8% gel daily
Trial: 11151744
Drug: Metronidazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (400 mg orally twice daily for 3 days)
Trial: 11151744
Drug: Placebo (matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matched placebo orally twice daily for 3 days)
Trial: 8314160
Drug: Epidoxorubicin, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidoxorubicin, 30 mg/m2 (P-E)
Trial: 8314160
Drug: Idarubicin, 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin, 6 mg/m2 (P-I)
Trial: 26921360
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin 3 mg/m2
Trial: 26921360
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin 6 mg/m2
Trial: 22203366
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of GABA
Trial: 20185343
Drug: Intra-articular sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular sodium hyaluronate (SH) injections (5 injections at weekly intervals)
Trial: 20185343
Drug: Physiologic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic saline solution injections (5 injections at weekly intervals)
Trial: 10606280
Drug: Cyclophosphamide, estramustine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide, estramustine, or no therapy for 2 years (in NPCP 900/1000 trial)
Trial: 6337742
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (40 mg orally every 6 hours for 12 weeks)
Trial: 6337742
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (chronic therapy)
Trial: 24444414
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy (omeprazole 20 mg od)
Trial: 24444414
Drug: On-demand therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand therapy (omeprazole 20 mg on-demand)
Trial: 24444414
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy (omeprazole 20 mg od) in NERD
Trial: 24444414
Drug: On-demand therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand therapy (omeprazole 20 mg on-demand) in NERD
Trial: 24444414
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy (omeprazole 20 mg od) in RE
Trial: 24444414
Drug: On-demand therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand therapy (omeprazole 20 mg on-demand) in RE
Trial: 22943930
Drug: DDB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDB plus garlic oil (GO) - 2 capsules per day
Trial: 22943930
Drug: DDB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDB plus garlic oil (GO) - 3 capsules per day
Trial: 22943930
Drug: DDB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDB plus garlic oil (GO) - 6 capsules per day
Trial: 22943930
Drug: DDB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDB plus garlic oil (GO) - all doses
Trial: 15338257
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of Anti-oxLDL levels with anticardiolipin antibodies
Trial: 15338257
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of Anti-oxLDL levels with beta(2)-glycoprotein I antibodies
Trial: 11349744
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of ceftazidime 3 g/day
Trial: 11349744
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of ceftazidime 2 g 3 times/day
Trial: 11349744
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of ceftazidime
Trial: 9625813
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with modified CODBLAM IV regimen
Trial: 9625813
Drug: Ara‐C at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ara‐C at low doses plus alphaIFN
Trial: 9625813
Drug: alphaIFN as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alphaIFN as maintenance therapy
Trial: 7943077
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 gel (0.5 mg, two doses 6 hours apart)
Trial: 7943077
Drug: Low-dose oxytocin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oxytocin (12 hours, up to 4 mlU/min)
Trial: 31978882
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of preoperative hydrocortisone (group HC, n = 20)
Trial: 31978882
Drug: Postoperative 3-month
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Postoperative 3-month pituitary hormone outcomes including ACTH deficiency
Trial: 26830074
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy alone (32%) or in combination with other agents (17%)
Trial: 23307105
Drug: Topical fluoroquinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluoroquinolone use at presentation
Trial: 10821722
Drug: Bambuterol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bambuterol (10 mg or 20 mg tablets once daily)
Trial: 10821722
Drug: Terbutaline (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (2.5 mg tablets three times daily)
Trial: 10821722
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Bambuterol and Terbutaline)
Trial: 8876850
Drug: Methyl salicylate
RxNorm normalized name: Methyl Salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyl salicylate (12.5%) applied as an ointment, 5 g twice daily for 4 days (8 doses)
Trial: 8876850
Drug: Trolamine salicylate
RxNorm normalized name: Trolamine Salicylate
DrugBank: Trolamine salicylate (DB11079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trolamine salicylate (10%) applied as a cream, 5 g twice daily for two doses
Trial: 1545094
Drug: Oral challenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral challenges to fish species